行情

ADVM

ADVM

Adverum
NASDAQ

实时行情|Nasdaq Last Sale

9.37
+0.36
+4.00%
盘后: 9.37 0 0.00% 17:07 11/15 EST
开盘
9.01
昨收
9.01
最高
9.38
最低
8.88
成交量
86.61万
成交额
--
52周最高
16.38
52周最低
2.810
市值
6.05亿
市盈率(TTM)
-9.7310
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADVM 新闻

  • 屡破新高美股向上空间或打开 美联储将成为拦路虎?
  • 第一财经.1小时前
  • 消息人士:沙特阿美将不会在美国上市
  • 新浪美股.1小时前
  • 美国零售业遇“寒冬”,TJX为何能独领风骚?
  • 新浪财经-自媒体综合.2小时前
  • 第三季度营收大增28.7%,京东的加速度与下沉路
  • 海外网.4小时前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

ADVM 简况

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.
展开

Webull提供Adverum Biotechnologies Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。